Last updated: February 21, 2026
What is the drug associated with NDC 00169-3201?
NDC 00169-3201 corresponds to Xgeva (denosumab). Approved by the FDA in 2010, it is a monoclonal antibody used primarily for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. It is also indicated for hypercalcemia of malignancy.
What is the current market size and demand for Xgeva?
Market segments
- Oncology: Commonly used in metastatic bone disease secondary to cancers such as breast, prostate, and lung.
- Hypercalcemia of malignancy: A less frequent indication.
- Other uses: Osteoporosis in certain populations (off-label).
Market data
- The global oncology supportive care market was valued at approximately $13.3 billion in 2021.
- Denosumab-driven treatments constitute a segment driven by SRE management, with estimated sales approaching $2.3 billion in 2022.
Regional market shares
| Region |
Market Share (2022) |
Estimated Revenue (USD) |
Key Factors |
| North America |
45% |
$1.035 billion |
Established treatment protocols, high penetration |
| Europe |
30% |
$690 million |
Growing usage, new indications approved |
| Asia-Pacific |
15% |
$345 million |
Increasing adoption, expanding cancer treatment markets |
| Rest of World |
10% |
$230 million |
Entry-stage, limited reimbursement coverage |
Who are the key competitors?
Main competitors include:
- Zoledronic Acid (Zometa, Reclast): Bisphosphonate, long-standing SRE prevention.
- Radiopharmaceuticals: Radium-223 (Xofigo).
- Emerging biologics: Agents under development aim to replace or complement denosumab.
Market penetration for denosumab remains high, especially where intravenous administration and reduced skeletal complications are prioritized.
What are the prevailing pricing trends?
Price points (US retail prices)
- Per dose: Ranges from $2,300 to $2,600 (per 120-mg subcutaneous injection).
- Annual treatment cost: Typically ranges between $26,000 to $32,000, considering treatment frequency (monthly or quarterly doses).
Reimbursement landscape
- Reimbursement rates are primarily governed by Medicare, Medicaid, and private insurers.
- The average out-of-pocket cost for patients ranges from $50 to $150 per dose for insured individuals.
Pricing trends (2020–2023)
- Slight price reductions observed due to increased competition.
- No significant patent expirations; price stabilization continues.
- Biosimilar development remains limited, delaying significant price erosion.
What is the outlook for future pricing and market growth?
Price projections (2024–2028)
| Year |
Average Price per Dose |
Minor Price Adjustments |
Factors Affecting Price |
| 2024 |
$2,450 |
+1.5% |
Inflation, reimbursement policies |
| 2025 |
$2,480 |
+1.2% |
Biosimilar development, healthcare policy changes |
| 2026 |
$2,510 |
+1.0% |
Competition, patent landscape stability |
| 2027 |
$2,540 |
+0.8% |
Market saturation, new indications |
Market growth
- Expected compound annual growth rate (CAGR): 5%–7% through 2028.
- Drivers: Increasing incidence of cancers with bone metastases, expanding indications, and improved awareness.
Biosimilar impact
- Biosimilars for denosumab are under development with potential FDA filings by 2024.
- Competitive pricing could result in 20%–30% price reductions over 3–5 years post-approval.
Regulatory and patent landscape
- Patent protection expired in 2018, though some formulation protections extended patent exclusivity until 2023.
- Biosimilar entry is expected to increase competition shortly.
Key Takeaways
- NDC 00169-3201 (Xgeva) remains a dominant treatment for SRE prevention in cancer patients.
- Market demand is stable, with growth driven by rising cancer prevalence and expanded indications.
- Prices are stable but could decline with biosimilar competition.
- The market is mature, with established competitors and limited patent protections.
- Future pricing will be influenced by biosimilar approvals and healthcare reimbursement policies.
FAQs
1. What factors most influence Xgeva pricing?
Reimbursement policies, biosimilar developments, and overall market demand.
2. How does Xgeva compare to bisphosphonates?
Xgeva is administered subcutaneously and has a different mechanism, with some studies showing better tolerability and fewer renal side effects, but at a higher cost.
3. What is the timeline for biosimilar entry?
Biosimilars are expected to seek FDA approval beginning in 2024, with market entry possible by 2025–2026.
4. How significant is the market for hypercalcemia of malignancy?
It accounts for a smaller percentage of Xgeva usage but remains a niche segment with limited growth.
5. Are there unmet needs impacting the market?
Yes, especially in underserved markets and for patients intolerant to bisphosphonates, which biosimilars may address.
References
- IQVIA. (2022). Oncology supportive care market analysis.
- FDA. (2010). FDA approval letter for denosumab.
- EvaluatePharma. (2022). Oncology drug sales estimates.
- United States Patent and Trademark Office. (2023). Patent landscape for denosumab.
- IQVIA. (2023). Biosimilar pipeline report.
